Efficacy and safety of empegfilgrastim, a novel pegylated G-CSF: Results of complete analysis after 4 cycles of myelosuppressive chemotherapy in phase III double-dummy randomized clinical study

Autor:	Sergey Panchenko, Sergei Tjulandin, Julia S. Shapovalova, Olga Filon, Daniil Stroyakovskiy, Marina Nechaeva, Petr Krivorotko, Olga Burdaeva, Guzel Mukhametsina, Marina Matrosova, Ludmila P. Sheveleva, Igor Lifirenko, Vladimir Ivanovich Vladimirov, Nadezhda V. Kovalenko, Roman Ivanov, Mikhail V. Kopp, Pavel Skopin, Anastasia Abrosimova, Irina A. Jelvakova
Předmět:	Oncology Cancer Research medicine.medical_specialty Myelosuppressive Chemotherapy business.industry Empegfilgrastim Neutropenia medicine.disease Clinical study Innovator Internal medicine medicine Drug product In patient business
Zdroj:	Web of Science
Popis:	e20735 Background: Empegfilgrastim is an innovator drug product of pegylated G-CSF indicated for prophylaxis of neutropenia in patients receiving myelosuppressive chemotherapy. Methods: Objective w...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7b48118a4cab5cb537488669c9372ed https://publons.com/wos-op/publon/18351161/ Zobrazit plný text záznamu